Measurement of airway ion transport assists the diagnosis of cystic fibrosis

Pediatric Pulmonology

Volumn 45, Issue 8, 2010, Pages 789-795

  Middleton, Peter G ^a   House, Hugh H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chloride; Cystic fibrosis; Membrane potentials; Nasal potential difference; Sodium

Indexed keywords

AMILORIDE; CHLORIDE ION; ISOPRENALINE; SODIUM ION;

ARTICLE; CHLORIDE TRANSPORT; CLASSIFICATION ALGORITHM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; LUNG FIBROSIS; NASAL POTENTIAL DIFFERENCE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT PARAMETERS; SODIUM TRANSPORT; SQUAMOUS EPITHELIUM;

ADOLESCENT; ADULT; AMILORIDE; CHLORIDES; COHORT STUDIES; CYSTIC FIBROSIS; EPITHELIUM; FEMALE; HUMANS; ION TRANSPORT; ISOPROTERENOL; MALE; MEMBRANE POTENTIALS; NASAL MUCOSA; SODIUM; YOUNG ADULT;

EID: 77956103863     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21253     Document Type: Article

References (23)

1. Middleton PG, Geddes DM, Alton EWFW. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994;7:2050-2056.
2. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-455.
3. Jaron R, Yaakov Y, Rivlin J, Blau H, Bentur L, Yahav Y, Kerem E, Bibi H, Picard E, Wilschanski M. Nasal potential difference in non-classic cystic fibrosis - long term follow up. Pediatr Pulmonol 2008;43:545-549. (Pubitemid 351813007)
4. Alton EWFW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddes DM. Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 1990;3:922-926.
5. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006;61:627-635.
6. Middleton PG, Geddes DM, Alton EWFW. Trimethoprim and tetracycline inhibit airway epithelial sodium absorption. Am J Respir Crit Care Med 1996;154:18-23.
7. Middleton PG, Pollard KA, Wheatley JR. Hypertonic saline alters ion transport across the normal airway epithelium. Eur Respir J 2001;17:195-199.
8. Smith SN, Middleton PG, Chadwick S, Jaffe A, Bush KA, Rolleston S, Farley R, Delaney SJ, Wainwright B, Geddes DM, Alton EWFW. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am J Respir Cell Mol Biol 1999;20:129-134.
9. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349:1433-1441.
10. Middleton PG, Pollard KA, Donohoo E, Wheatley JR, Geddes DM, Alton EWFW. Airway surface liquid calcium modulates chloride permeability in the cystic fibrosis airway. Am J Respir Crit Care Med 2003;168:1223-1226. (Pubitemid 37421840)
11. Sweezey NB, Smith D, Corey M, Ellis L, Carpenter S, Tullis DE, Durie P, O'Brodovich HM. Amiloride-insensitive nasal potential difference varies with the menstrual cycle in cystic fibrosis. Pediatr Pulmonol 2007;42:519-524.
12. Ahrens RC, Standaert TA, Launspach J, Han SH, Teresi ME, Aitken ML, Kelley TJ, Hilliard KA, Milgram LJ, Konstan MW, Weatherly MR, McCarty NA. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 2002;33: 142-150.
13. Boyle MP, Diener-West M, Milgram L, Knowles MR, Foy C, Zeitlin PL, Standaert TA. A multicenter study of the effect of solution temperature on nasal potential difference measurements. Chest 2003;124:482-489.
14. House HH, Middleton PG. Impact of different chloride and glucose solutions on nasal potential difference. Pediatr Pulmonol 2009;44:645-648.
15. Middleton PG, Caplen NJ, Gao X, Huang L, Gaya H, Geddes DM, Alton EWFW. Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth. Eur Respir J 1994;7:442-445. (Pubitemid 24099002)
16. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW III. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-S14.
17. Wilschanski M, Famini H, Strauss-Liviatan N, Rivlin J, Blau H, Bibi H, Bentur L, Yahav Y, Springer H, Kramer MR, Klar A, Ilani A, Kerem B, Kerem E. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001;17: 1208-1215.
18. Bland JM, Altman DG. Statistics notes: measurement error. Br Med J 1996;313:744.
19. Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, Hunter J, Berclaz PY, Brass L, Zeitlin PL, Hammond K, Davies Z, Foy C, Noone PG, Knowles MR. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 2004;37:385-392.
20. Caplen NJ, Alton EWFW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C, Huang L, Porteous DJ, Williamson R, Geddes DM. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med 1995;1:39-46.
21. Middleton PG. Cystic fibrosis ion transport and the effect of CFTR gene transfer. PhD thesis, University of London; 1995.
22. Yaakov Y, Kerem E, Yahav Y, Rivlin J, Blau H, Bentur L, Aviram M, Picard E, Bdolah-Abram T,Wilschanski M. Reproducibility of nasal potential difference measurements in Cystic Fibrosis. Chest 2007;132:1219-1226.
23. Osborne LR, Lynch M, Middleton PG, Alton EWFW, Geddes DM, Pryor JP, Hodson ME, Santis GK. Nasal epithelial ion transport and genetic analysis of infertile men with congenital bilateral absence of the vas deferens. Hum Mol Genet 1993;2: 1605-1609.